Alzheimer

Donepezil is indicated for treatment of mild to moderate and severe dementia of the Alzheimer's type and Improvement of dementia accompanied by celebro-vascular disease. Donepezil is currently the only molecule approved for all the levels of Alzheimer's syndrome, from mild to severe. Alzheimer's disease is a market worth 2.8 Billion Dollar in 2008 in the 7 major markets. Donepezil is currently the undisputed market leader with more than 1.5 Billion Dollar sale in 2008, more than half of the total Alzheimer's market.

APR developed the proprietary RapidFilm™ technology which is a novel, non-mucoadhesive, fast dissolving oral dosage form based on a water soluble polymer. Placed on top of the tongue, the film disperses within seconds (water is not needed), promoting a gastrointestinal absorption comparable to immediate release oral solid dosage forms.

The Donepezil RapidFilm® was especially designed for higher patient compliance. Considering that the target population is almost totally made of elder people, Donepezil RapidFilm offers multiple competitive advantages versus the already marketed pharmaceutical forms of Donepezil: higher compliance swallowing is easy and water is not needed, the RapidFilm, once put in the mouth, cannot be extracted.